IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 42.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,805 shares of the medical research company’s stock after acquiring an additional 2,019 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in IQVIA were worth $1,337,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at about $33,000. GKV Capital Management Co. Inc. purchased a new stake in IQVIA in the fourth quarter valued at approximately $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA in the 4th quarter valued at $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Barclays lowered their price target on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 7th. Truist Financial reduced their price objective on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research note on Thursday, April 10th. UBS Group decreased their price objective on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $228.14.

IQVIA Trading Up 0.9%

Shares of IQV stock opened at $144.90 on Wednesday. The stock has a market cap of $25.07 billion, a P/E ratio of 19.32, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The business has a fifty day simple moving average of $158.26 and a 200-day simple moving average of $184.98.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. During the same period in the prior year, the company earned $2.54 EPS. The firm’s revenue was up 2.5% on a year-over-year basis. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.